Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis — Stella

Home/Cirrhosis/Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis

View on ClinicalTrials.gov

Recruiting

Back to Cirrhosis trials

Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(1 site)

Pakistan

Asian Institute of Medical Sciences, Hyderābād, Sindh

Key details

Phase

Post-approval study

Sponsor

Asian Institute Of Medical Sciences

Enrollment target

~220 participants

Started

April 2026

Primary completion

April 2027

Age range

18 Years and older

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.